Sign in Subscribe

TScan Therapeutics Pauses Solid Tumor Trial to Prioritize Heme, and Extends Cash Runway into Second Half of 2027

TScan Therapeutics (TCRX) announced a major strategic shift, securing FDA alignment for its pivotal TSC-101 trial for blood cancers, improving manufacturing speed, and cutting costs to extend its financial health into the second half of 2027.

TScan Therapeutics Pauses Solid Tumor Trial to Prioritize Heme, and Extends Cash Runway into Second Half of 2027
Credit: TScan Therapeutics
Already have an account? Sign in.